Delayed-onset	delayed-onset	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
presents	presents	O	O	O	O
5	5	O	O	O	O
to	to	O	O	O	O
12	12	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
without	without	O	O	O	O
arterial	arterial	O	O	O	O
or	or	O	O	O	O
venous	venous	O	O	O	O
thromboemboli	thromboemboli	O	O	OTHERS	I
.	.	O	O	O	O

Delayed	delayed	O	O	O	O
recognition	recognition	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
contribute	contribute	O	O	O	O
to	to	O	O	O	O
poor	poor	O	O	O	O
patient	patient	O	O	O	O
outcomes	outcomes	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
describe	describe	O	O	O	O
and	and	O	O	O	O
increase	increase	O	O	O	O
awareness	awareness	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
clinical	clinical	O	O	O	O
scenario	scenario	O	O	O	O
in	in	O	O	O	O
which	which	O	O	O	O
the	the	O	O	O	O
onset	onset	O	O	O	O
or	or	O	O	O	O
manifestations	manifestations	O	O	O	O
of	of	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
are	are	O	O	O	O
delayed	delayed	O	O	O	O
.	.	O	O	O	O

DESIGN	design	O	O	O	O
:	:	O	O	O	O
Retrospective	retrospective	O	O	O	O
case	case	O	O	O	O
series	series	O	O	O	O
.	.	O	O	O	O

SETTING	setting	O	O	O	O
:	:	O	O	O	O
Three	three	O	O	O	O
large	large	O	O	O	O
urban	urban	O	O	O	O
hospitals	hospitals	O	O	O	O
(	(	O	O	O	O
with	with	O	O	O	O
active	active	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
surgery	surgery	O	O	O	O
programs	programs	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
:	:	O	O	O	O
14	14	O	O	O	O
patients	patients	O	O	O	O
seen	seen	O	O	O	O
over	over	O	O	O	O
a	a	O	O	O	O
3-year	3-year	O	O	O	O
period	period	O	O	O	O
in	in	O	O	O	O
whom	whom	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
became	became	O	O	O	O
apparent	apparent	O	O	O	O
on	on	O	O	O	O
delayed	delayed	O	O	O	O
presentation	presentation	O	O	O	O
with	with	O	O	O	O
thromboembolic	thromboembolic	O	DISEASE	OTHERS	I
complications	complications	O	O	O	O
.	.	O	O	O	O

MEASUREMENTS	measurements	O	O	O	O
:	:	O	O	O	O
Platelet	platelet	O	O	O	O
counts	counts	O	O	O	O
,	,	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
objectively	objectively	O	O	O	O
determined	determined	O	O	O	O
thromboembolism	thromboembolism	O	O	OTHERS	I
,	,	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
platelet	platelet	CHEMICALS	O	OTHERS	I
factor	factor	CHEMICALS	O	OTHERS	I
4	4	CHEMICALS	O	OTHERS	I
antibody	antibody	O	O	O	O
tests	tests	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
outcomes	outcomes	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
went	went	O	O	O	O
home	home	O	O	O	O
after	after	O	O	O	O
hospitalizations	hospitalizations	O	O	O	O
that	that	O	O	O	O
had	had	O	O	O	O
included	included	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
--	--	O	O	O	O
in	in	O	O	O	O
most	most	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
no	no	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
recognized	recognized	O	O	O	O
--	--	O	O	O	O
only	only	O	O	O	O
to	to	O	O	O	O
return	return	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
hospital	hospital	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
,	,	O	O	O	O
day	day	O	O	O	O
14	14	O	O	O	O
)	)	O	O	O	O
with	with	O	O	O	O
thromboembolic	thromboembolic	O	DISEASE	OTHERS	I
complications	complications	O	O	O	O
.	.	O	O	O	O

Thromboemboli	thromboemboli	O	O	OTHERS	I
were	were	O	O	O	O
venous	venous	O	O	O	O
(	(	O	O	O	O
12	12	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
7	7	O	O	O	O
with	with	O	O	O	O
pulmonary	pulmonary	O	O	OTHERS	I
emboli	emboli	O	O	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
arterial	arterial	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
both	both	O	O	O	O
.	.	O	O	O	O

Platelet	platelet	O	O	O	O
counts	counts	O	O	O	O
were	were	O	O	O	O
mildly	mildly	O	O	O	O
decreased	decreased	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
but	but	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
on	on	O	O	O	O
second	second	O	O	O	O
presentation	presentation	O	O	O	O
.	.	O	O	O	O

On	on	O	O	O	O
readmission	readmission	O	O	O	O
,	,	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
received	received	O	O	O	O
therapeutic	therapeutic	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
worsened	worsened	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
'	'	O	O	O	O
clinical	clinical	O	O	O	O
condition	condition	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
11	11	O	O	O	O
cases	cases	O	O	O	O
,	,	O	O	O	O
decreased	decreased	O	O	O	O
the	the	O	O	O	O
platelet	platelet	O	O	O	O
count	count	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
at	at	O	O	O	O
readmission	readmission	O	O	O	O
,	,	O	O	O	O
143	143	O	O	O	O
x	x	O	O	O	O
10(9	10(9	O	O	O	O
)	)	O	O	O	O
cells/L	cells/l	O	O	O	O
;	;	O	O	O	O
mean	mean	O	O	O	O
nadir	nadir	O	O	O	O
after	after	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
re-exposure	re-exposure	O	O	O	O
,	,	O	O	O	O
39	39	O	O	O	O
x	x	O	O	O	O
10(9	10(9	O	O	O	O
)	)	O	O	O	O
cells/L	cells/l	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Results	results	O	O	O	O
of	of	O	O	O	O
serologic	serologic	O	O	O	O
tests	tests	O	O	O	O
for	for	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
antibodies	antibodies	O	O	O	O
were	were	O	O	O	O
positive	positive	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Subsequent	subsequent	O	O	O	O
treatments	treatments	O	O	O	O
included	included	O	O	O	O
alternative	alternative	O	O	O	O
anticoagulants	anticoagulants	O	O	O	O
(	(	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
thrombolytic	thrombolytic	O	O	O	O
drugs	drugs	O	O	O	O
(	(	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
inferior	inferior	O	O	O	O
vena	vena	O	O	O	O
cava	cava	O	O	O	O
filters	filters	O	O	O	O
(	(	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
eventually	eventually	O	O	O	O
,	,	O	O	O	O
warfarin	warfarin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Three	three	O	O	O	O
patients	patients	O	O	O	O
died	died	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Delayed-onset	delayed-onset	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
is	is	O	O	O	O
increasingly	increasingly	O	O	O	O
being	being	O	O	O	O
recognized	recognized	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
avoid	avoid	O	O	O	O
disastrous	disastrous	O	O	O	O
outcomes	outcomes	O	O	O	O
,	,	O	O	O	O
physicians	physicians	O	O	O	O
must	must	O	O	O	O
consider	consider	O	O	O	O
heparin-induced	heparin-induced	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
whenever	whenever	O	O	O	O
a	a	O	O	O	O
recently	recently	O	O	O	O
hospitalized	hospitalized	O	O	O	O
patient	patient	O	O	O	O
returns	returns	O	O	O	O
with	with	O	O	O	O
thromboembolism	thromboembolism	O	O	OTHERS	I
;	;	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
alternative	alternative	O	O	O	O
anticoagulants	anticoagulants	O	O	O	O
,	,	O	O	O	O
not	not	O	O	O	O
heparin	heparin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
initiated	initiated	O	O	O	O
.	.	O	O	O	O

